Oral Vaccination with Recombinant *Yersinia enterocolitica* Expressing Hybrid Type III Proteins Protects Gerbils from Amebic Liver Abscess

Hannelore Lotter, Holger Rüssmann, Jürgen Heesemann and Egbert Tannich


Updated information and services can be found at: [http://iai.asm.org/content/72/12/7318](http://iai.asm.org/content/72/12/7318)

**REFERENCES**

This article cites 24 articles, 17 of which can be accessed free at: [http://iai.asm.org/content/72/12/7318#ref-list-1](http://iai.asm.org/content/72/12/7318#ref-list-1)

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), [more »](http://iai.asm.org/content/72/12/7318#ref-list-1)
Oral Vaccination with Recombinant Yersinia enterocolitica Expressing Hybrid Type III Proteins Protects Gerbils from Amebic Liver Abscess

Hannelore Lotter,1 Holger Rüssmann,2 Jürgen Heesemann,2 and Egbert Tannich1*

Department of Molecular Parasitology, Bernhard Nocht Institute for Tropical Medicine, Hamburg,1 and Max von Pettenkofer Institute for Hygiene and Medical Microbiology, Ludwig Maximilians University Munich, Munich,2 Germany

Received 3 May 2004/Returned for modification 7 June 2004/Accepted 24 August 2004

Protection against invasive amebiasis was achieved in the gerbil model for amebic liver abscess by oral immunization with live attenuated Yersinia enterocolitica expressing the Entamoeba histolytica galactose-inhibitable lectin that has been fused to the Yersinia outer protein E (YopE). Protection was dependent on the presence of the YopE translocation domain but was independent from the antibody response to the ameba lectin.

The intestinal protozoan parasite Entamoeba histolytica, the causative agent of human amebiasis, is endemic in large parts of the world and is considered to be responsible for tens of millions of cases of dysentery and liver abscess each year (22). Morbidity and mortality associated with amebic infection have persisted despite the availability of effective therapy, suggesting that interventions designed to reduce or eliminate disease are needed. Since humans are the only relevant host for E. histolytica, a sufficient vaccine could potentially eradicate amebiasis.

A leading candidate for a vaccine to prevent amebiasis is the E. histolytica galactose- and N-acetylgalactosamine-inhibitable surface lectin (12). Various independent vaccination trials of intraperitoneal immunization with either the purified native molecule or recombinantly expressed sections of the 170-kDa heavy subunit revealed substantial protection in the gerbil model for amebic liver abscess (1, 9–11, 18, 24). In contrast to systemic application, oral vaccination of gerbils with the lectin, either fused to the B subunit of cholera toxin (9) or somatically expressed in an attenuated Salmonella strain, revealed only little protection against liver abscess formation (11, 23). Thus, it appears that the delivery system for an oral amebiasis vaccine has to be improved.

Recent progress in the development of bacterial live carrier vaccines has been made by the use of the type III secretion systems (T3SS) for heterologous antigen delivery (4). The Yersinia enterocolitica T3SS has been used successfully to translocate heterologous proteins into host cells (7, 20). This translocation was achieved by fusion of proteins to at least 50 amino acids (aa) of the N terminus of YopE (19). However, shortening of the YopE N terminus to 18 amino acid residues abolished translocation into host cells but led to secretion of the chimeric proteins into the culture medium (16, 17, 20). Recently, it was shown for mice that oral application of recombinant Yersinia cells expressing listeriolysin via T3SS resulted in a protective immune response against listeria infection (14, 15).

In order to assess the vaccine potential of YopE-directed antigen delivery against amebiasis, we generated attenuated recombinant Yersinia enterocolitica O8 cells, which either secrete or translocate YopE-lectin hybrid proteins via the T3SS. DNA fragments, encoding various segments of the 170-kDa heavy subunit of the E. histolytica surface lectin, were ligated in frame to the sequences for the 18-aa YopE secretion (YopE-S) or the 138-aa YopE secretion and translocation (YopE-T) domain and cloned into the Yersinia expression plasmid pACYC184 (15) conferring chloramphenicol resistance (Fig. 1A). Plasmids were transformed into attenuated Yersinia strain WA irp1 (abolished yersiniabactin production) (13), as this strain was found to colonize the intestine and Peyer’s patches of orally infected gerbils but did not disseminate to other organs and kill the animals as wild-type cells do. With the exception of YopE-S-170PR transformants, recombinant Yersinia cells were able to express all of the various fusion proteins, as revealed by Western blots prepared from bacterial lysates and developed with antilectin immune serum (Fig. 1B, upper panel). In addition, a number of the various hybrid proteins were released and could be detected in yersinia culture supernatants (Fig. 1B, lower panel). Two of the four secreted proteins were released only in the presence of the YopE secretion and translocation domain. Consistent with release via the T3SS pathway, coculture experiments of recombinant bacteria with HeLa cells (15) revealed that only fusion proteins containing the YopE secretion and translocation domain were targeted to the HeLa cell cytosol (data not shown).

Recombinant Yersinia cells able to secrete or translocate YopE-lectin fusion proteins were used for oral vaccination of gerbils. Intragastric application of 109 CFU resulted in long-lasting intestinal colonization for at least 30 days. However, culturing of reisolated bacteria under chloramphenicol selection indicated differences in the stability of the expression plasmid between the various transformants. Whereas most of
the reisolated bacteria (50 to 70%) from the majority of trans-
formants were chloramphenicol resistant for up to at least 14
days of colonization, all *Yersinia* cells initially expressing
YopE-T-170EC or YopE-T-170CR2 did not grow in the pres-
ence of chloramphenicol, even when they were reisolated as
early as 3 days postinoculation (data not shown). Accordingly,
a vaccination scheme was applied in which gerbils were in-
fected with repeated doses of recombinant *Yersinia* cells given
once per week for four consecutive weeks. Subsequently, ani-
mals were treated with antibiotics to eliminate remaining bac-
teria and then challenged by intrahepatic inoculation of $10^5$
axenically cultured *E. histolytica* trophozoites (3). Seven days
later, animals were sacrificed, and the livers were entirely re-
moved, sectioned, and inspected for the presence of abscesses.

In cases where abscesses were present, the weight of abscesses
relative to total liver weight was determined. Animals vacci-
nated with the attenuated nontransformed *Yersinia* strain WA
irp1 served as controls. The results indicated clear differences
between control animals and those vaccinated with *Yersinia*
cells expressing the various YopE-lectin proteins. In all
groups, some degree of protection was observed. However,
differences in the levels of protection were statistically signifi-
cant only with *Yersinia* cells transformed either with YopE-T-
170CP or YopE-T-170CR2 (Table 1). The protective potential
of 170CR2 to inhibit amebic liver abscess in gerbils has been
shown previously (9, 10). However, the potential of 170CP to
induce protective immunity is surprising, as previous studies
have shown that high titers of serum immunoglobulin G anti-

---

**FIG. 1.** Expression and secretion of YopE-lectin hybrid proteins. (A) Shown are the structural domains of the *E. histolytica* 170-kDa surface
lectin as they have been defined previously (10, 21). Numbering refers to amino acid residues and indicates the boundaries of fragments
recombinantly expressed as fusions with the YopE secretion (YopE18) or the YopE secretion and translocation (YopE138) domain. (B) Immuno-
blots of lysates and culture supernatants from *Yersinia* cells transformed with the various YopE-lectin expression plasmids, which were developed
with an antilectin immune serum.
TABLE 1. Protection of gerbils from amebic liver abscess by oral vaccination with recombinant Y. enterocolitica WA ipl expressing various YopE-lectin fusion proteins

<table>
<thead>
<tr>
<th>Vaccine group</th>
<th>No. of gerbils with liver abscesses/ no. of gerbils challenged</th>
<th>% of gerbils protected</th>
<th>Size of liver abscess in nonprotected animals (% of control)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>WA ipl (control)</td>
<td>46/48</td>
<td>4.2</td>
<td></td>
</tr>
<tr>
<td>YopE-T-170EC</td>
<td>6/10</td>
<td>40.0</td>
<td>68.6</td>
</tr>
<tr>
<td>YopE-T-170CP</td>
<td>3/10</td>
<td>70.0</td>
<td>45.3 C</td>
</tr>
<tr>
<td>YopE-S-170CRc</td>
<td>13/14</td>
<td>7.1</td>
<td>52.9</td>
</tr>
<tr>
<td>YopE-T-170Crc</td>
<td>8/11</td>
<td>27.3</td>
<td>82.4</td>
</tr>
<tr>
<td>YopE-S-170CR2</td>
<td>10/15</td>
<td>33.3</td>
<td>58.7</td>
</tr>
<tr>
<td>YopE-T-170CR2</td>
<td>5/14</td>
<td>64.3 B</td>
<td>34.8 D</td>
</tr>
</tbody>
</table>

* Significant differences from WA ipl control, as determined by Fisher’s exact test, are indicated by A, P < 0.002; B, P < 0.001; C, P < 0.05; and D, P < 0.005.

bodies to this fragment exacerbate amebic disease (10). Interestingly, analysis of antibody responses after oral infection with recombinant *Yersinia* cells indicated that the observed protection was most likely mediated by antibody-independent immune mechanisms, as antibody titers were relatively low compared to those from previous intraperitoneal vaccination trials with recombinant ameba lectin (10) and there was no correlation between the degree of protection and titers of antibodies (Fig. 2). Because of the lack of immunological markers in the gerbil model, we can only speculate about the mechanism responsible for the observed protection. Recently, it has been shown that mice orally immunized with *Yersinia* cells expressing YopE chimeric proteins under control of the YopE translocation domain but not under control of the YopE secretion domain develop CD8 and CD4 T cells which secrete high levels of gamma interferon and tumor necrosis factor alpha upon stimulation with corresponding antigens (14). On the other hand, it is well documented that activation of macrophages leading to the production of nitric oxide is important to control amebic infection (2, 5, 6, 8, 17). Thus, immunization with *Yersinia* cells expressing YopE-lectin hybrid proteins under control of the YopE translocation domain might induce the production of gamma interferon and tumor necrosis factor alpha by specifically stimulated CD4 T cells, which will result in activation of macrophages and finally in host defense against invading *E. histolytica*. Thus, the application of gram-negative bacteria delivering appropriate ameba antigen via the T3SS might constitute a promising new strategy for the development of an oral amebiasis vaccine.

We thank Claudia Marggraff and Ina Hennings for skilful technical assistance.

H.R., J.H., and E.T. were supported by the Deutsche Forschungsgemeinschaft (priority program “new vaccination strategies”; RU838/1-2, HE1297/9-2, and TA1107-2).

REFERENCES


Editor: J. B. Bliska